ASH 2024: Multiple Myeloma Studies May Change Practice
Research presented at ASH 2024 could change the treatment of patients with newly diagnosed and relapsed or refractory MM, according to experts.
Related Articles
China’s Leapfrog in New Drug Development
China has made significant strides in drug development over the past two decades, transitioning from being a producer of generic drugs to a…
How Ohio State experts brought us closer to a cancer-free world in 2024
2024 was a year of breakthroughs in cancer care, research and knowledge at Ohio State, where oncology experts look ahead to opportunities to innovate in…
FDA approves remestemcel-L-rknd for steroid-refractory acute graft ver
On December 18, 2024, the Food and Drug Administration approved remestemcel-L-rknd (Ryoncil, Mesoblast, Inc.), an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for steroid-refractory…
The Use of HCT for Hematologic Cancers Across Patient Groups : Oncology Times
An abstract is unavailable.
FDA approves remestemcel-L-rknd for steroid-refractory acute graft ver
On December 18, 2024, the Food and Drug Administration approved remestemcel-L-rknd (Ryoncil, Mesoblast, Inc.), an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for steroid-refractory…
FDA Approves Remestemcel-L in Pediatric Patients With Acute GVHD
Following a complete response letter and biologics license application resubmission, the FDA has approved remestemcel-L for the treatment of pediatric patients with steroid-refractory acute graft-vs-host…
New Insights Into Secondary AML Treatment
Eunice S. Wang, MD, discusses research behind optimal therapy for acute myeloid leukemia secondary to other malignancies, particularly in patients with prior myelodysplastic syndrome.
FDA Approves Remestemcel-L in Pediatric SR-aGVHD
Data from the phase 3 MSB-GVHD001 trial support the FDA approval of rememstemcel-L in pediatric SR-aGVHD.
Are Medications to Prevent Breast Cancer Right for You?
If you’re worried about your risk for breast cancer, you’re not alone. That’s especially true if you have a family history of the disease. But…
FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease
The FDA has approved remestemcel-L-rknd for pediatric steroid-refractory acute graft-vs-host disease.
